Clonidine ER is a Small Molecule owned by Monopar Therapeutics, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.

Clonidine (Validive, BA-028) acts as adrenergic alpha 2 receptor agonist. It activates the alpha II receptor on macrophages and lymphocytes leading to the reduction of release of pro-inflammatory mediators such as tumor necrosis factor alpha (TNFalpha). Inhibition of tumor necrosis factor alpha and other inflammatory agents leads to relief from complication associated with radiotherapy and chemotherapy-induced oral mucositis.

The revenue for Clonidine ER is expected to reach a total of $350m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Clonidine ER NPV Report.

Clonidine ER is currently owned by Monopar Therapeutics.

Clonidine ER Overview

Clonidine ER (Validive, BA-028) is under development for the prevention and treatment of chemoradiation therapy-induced oral mucositis in patients with head and neck cancer. It is an extended release formulation administered through mucobuccal route as a tablet. It acts by targeting alpha-2 adrenergic receptor. The drug candidate is developed based on the Lauriad mucoadhesive technology.

Monopar Therapeutics Overview

Monopar Therapeutics (Monopar) is a clinical-stage biopharmaceutical company. It focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company’s pipeline products include validive, for chemoradiation induced SOM; camsirubicin, to treat advanced soft tissue sarcoma; MNPR-101 RIT, to treat advanced solid cancers, severe COVID-19; MNPR-101to treat solid cancers; MNPR-202, to treat advanced solid cancers. The company’s lead drug product candidate enters clinical development through collaboration with research center in the UK. It also carries out various phases of clinical trials. The company’s brands include Validive. Monopar is headquartered in Wilmette, Illinois, the US.

The operating loss of the company was US$9.1 million in FY2021, compared to an operating loss of US$6.5 million in FY2020. The net loss of the company was US$9.1 million in FY2021, compared to a net loss of US$6.3 million in FY2020.

Quick View – Clonidine ER

Report Segments
  • Innovator
Drug Name
  • Clonidine ER
Administration Pathway
  • Buccal
Therapeutic Areas
  • Toxicology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.